ArticleClinical pharmacology and therapeutics2026
Biography as the Missing Variable in Drug Development: A Case for Bio-Biographical Mechanistic Profiling.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most clinical trial failures reflect unmeasured biological heterogeneity. Biography - chronic stress, adversity, trauma, and social isolation-is a neglected source of that heterogeneity, operating through the same molecular pathways drugs engage. Independent studies in non-small cell lung cancer and melanoma have demonstrated that pretreatment biographical measurement predicts immune checkpoint inhibitor response through measurable immunological intermediaries, providing existence proof that this axis of heterogeneity is both detectable and pharmacologically consequential. Bio-biographical mechanistic profiling (BBMP) is the prospective, mechanism-matched measurement of biographical factors alongside standard biomarkers, designed to identify patients in whom biography has modified the pathway a drug is intended to engage. Matching treatment to pathway is not the same as matching treatment to a person in whom that pathway has been constituted by biography. BBMP is designed to close that gap.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.